29 May 2016
News from over in the UK indicates that a new revolutionary device developed by a team of Cambridge scientists is transforming the diagnosis of HIV in sub-Saharan Africa. The machine – known as Samba (simple amplification-based assay) – can tell whether a person is infected with the virus within two hours of them giving a tiny blood sample. Virus carriers can then be offered immediate treatment and advice.
More than 20 million people in sub-Saharan Africa are thought to be carrying HIV, the virus that causes Aids. The chaotic conditions in some parts of this region – with transport, health services and electricity supply often poor or nonexistent – have made it extraordinarily difficult for doctors to keep track of infected individuals.
But the new analyser, the size of a small coffee machine, which was developed by a team led by Cambridge blood scientist Professor Helen Lee, needs no laboratory or trained staff. It can be carried on a motorcycle – often the only method of transport in remote regions – and its reagents can withstand high temperatures and humidity. “Basically, they will still work even if the heat goes above 50C,” said Lee.
In recognition of her team’s achievement in developing Samba, Lee has been named a finalist in the 2016 European inventor awards. Winners will be announced in Lisbon next week.
“The crucial point about our device is that it provides you with a simple signal,” Lee told the Observer. “If two lights are produced, that shows a person has been infected with HIV. If only one light shines, they are not infected. We can show it to a patient and explain to them exactly what the lights mean and what is going on. That is a very powerful way to convince someone of their condition.”
Working in close collaboration with charity Médecins Sans Frontières, Lee and her colleagues have tested Samba on 40,000 men and women in Malawi and Uganda since the first prototype was developed in 2011 and found it works extremely efficiently. Each test costs around £12 to administer.
“Now we are going to expand testing for HIV to pregnant women, mothers and newborn children, starting in Kenya,” Lee said.
The ability to make quick diagnoses is considered to be of crucial importance in controlling Africa’s HIV epidemic. Until now, people have had to travel to health centres to provide a blood sample and then return weeks later for the results of their test. Up to 70% of patients will fail to return and are designated “lost to follow-up”. Lee’s tests should help to cut that number dramatically. “We are taking the test to the people rather than the other way around,” she said.
This point was backed by Benoît Battistelli, president of the European Patent Office, which is running next week’s inventor awards. “The test brings reliable diagnostics of HIV infection to areas where they are needed most and will also allow monitoring of the efficiency of medical treatments without laboratory infrastructure,” he said.
Apart from giving reliable diagnoses of HIV infection, Lee’s device can tell doctors the viral load – the amount of live virus material – that is flowing through a patient’s bloodstream. This a critical parameter for gauging drug dosages, and was previously available only in advanced laboratory settings.
Samba works by drawing a blood sample from a patient and then feeding it into a disposable cartridge that contains chemicals including a particular genetic sequence found only in HIV. These chemicals do not require refrigeration and amplify the viral DNA to generate a colour change that appears on the cartridge. Two red lines on the side mean that person is positive for HIV. One line means they are uninfected. No line means that the test has not worked and needs to be retaken.
“So many devices for dealing with conditions like HIV are created in the developed world,” said Lee. “Then scientists try to adapt them to suit the developing world. That always causes problems. So we have designed our system to suit developing countries from the start.
Lee has set up a new company, Diagnostics for the Real World, backed by the US National Institutes of Health and the Wellcome Trust, to raise money for manufacturing the device. There are also plans to use the system to test for other infectious diseases, including influenza and gonorrhoea.